Compare TSLX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | RCKT |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 401.6M |
| IPO Year | 2011 | N/A |
| Metric | TSLX | RCKT |
|---|---|---|
| Price | $17.39 | $3.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $21.61 | ★ $29.73 |
| AVG Volume (30 Days) | 709.7K | ★ 2.0M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.20 | $64.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.99 | $2.19 |
| 52 Week High | $25.17 | $6.43 |
| Indicator | TSLX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 38.94 | 39.28 |
| Support Level | $17.26 | $3.02 |
| Resistance Level | $18.65 | $3.52 |
| Average True Range (ATR) | 0.51 | 0.24 |
| MACD | -0.11 | -0.05 |
| Stochastic Oscillator | 4.60 | 25.69 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.